Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)

Subjects

Subjects :

medicine.medical_specialty
business.industry
Endocrinology, Diabetes and Metabolism
Semaglutide
Once weekly
030209 endocrinology & metabolism
General Medicine
Type 2 diabetes
030204 cardiovascular system & hematology
medicine.disease
03 medical and health sciences
0302 clinical medicine
Endocrinology
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
030212 general & internal medicine
business
Exenatide
medicine.drug

Details

ISSN :

14992671

Volume :

40

Database :

OpenAIRE

Journal :

Canadian Journal of Diabetes

Accession number :

edsair.doi.dedup.....8f428cc4a0367201c209e6de72788833

Full Text :

https://doi.org/10.1016/j.jcjd.2016.08.114